Clinical Trial Update: A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating alnuctamab in combination with mezigdomide in relapsed/refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Alnuctamab
• Mezigdomide (mezigdomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED